checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


OTEZLA is recommended as a treatment option for many clinical domains of psoriatic arthritis1

Click on a disease domain to the right to learn more

 

OTEZLA is included across multiple PsA domains1

OTEZLA is the only oral intracellular PDE4 inhibitor that modulates a network of cytokines implicated in PsA1

otzela is indicated across multiple psoriatic arthritis domainsotezla for skin psoriasisotezla for axial diseaseotezla for enthesitisotezla for peripheral arthritisotezla for nail psoriasisotezla for dactylitis
skin psoriasis treatment with otezlaaxial disease treatment with otezlaenthesitis treatment with otezlaperipheral arthritis treatment with otezlanail psoriasis treatment with otezladactylitis treatment with otezla

*OTEZLA is not included in the GRAPPA recommendation for axial disease.

CS, corticosteroid; DMARDs, disease-modifying antirheumatic drugs; GRAPPA, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; IA, intraarticular; IL, interleukin; LEF, leflunomide; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; PDE4, phosphodiesterase 4; phototx, phototherapy; PsA, psoriatic arthritis; SpA, spondyloarthritis; SSZ, sulfasalazine; TNF, tumour necrosis factor; vit, vitamin.

*OTEZLA is not included in the GRAPPA recommendation for axial disease.

CS, corticosteroid; DMARDs, disease-modifying antirheumatic drugs; GRAPPA, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; IA, intraarticular; IL, interleukin; LEF, leflunomide; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; PDE4, phosphodiesterase 4; phototx, phototherapy; PsA, psoriatic arthritis; SpA, spondyloarthritis; SSZ, sulfasalazine; TNF, tumour necrosis factor; vit, vitamin.

*OTEZLA is not included in the GRAPPA recommendation for axial symptoms.

CS, corticosteroid; DMARDs, disease-modifying antirheumatic drugs; GRAPPA, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; IA, intraarticular; IL, interleukin; LEF, leflunomide; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; PDE4, phosphodiesterase 4; phototx, phototherapy; PsA, psoriatic arthritis; SpA, spondyloarthritis; SSZ, sulfasalazine; TNF, tumour necrosis factor; vit, vitamin.

*OTEZLA is not included in the GRAPPA recommendation for axial disease.

CS, corticosteroid; DMARDs, disease-modifying antirheumatic drugs; GRAPPA, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; IA, intraarticular; IL, interleukin; LEF, leflunomide; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; PDE4, phosphodiesterase 4; phototx, phototherapy; PsA, psoriatic arthritis; SpA, spondyloarthritis; SSZ, sulfasalazine; TNF, tumour necrosis factor; vit, vitamin.

*OTEZLA is not included in the GRAPPA recommendation for axial disease.

CS, corticosteroid; DMARDs, disease-modifying antirheumatic drugs; GRAPPA, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; IA, intraarticular; IL, interleukin; LEF, leflunomide; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; PDE4, phosphodiesterase 4; phototx, phototherapy; PsA, psoriatic arthritis; SpA, spondyloarthritis; SSZ, sulfasalazine; TNF, tumour necrosis factor; vit, vitamin.

*OTEZLA is not included in the GRAPPA recommendation for axial disease.

CS, corticosteroid; DMARDs, disease-modifying antirheumatic drugs; GRAPPA, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; IA, intraarticular; IL, interleukin; LEF, leflunomide; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; PDE4, phosphodiesterase 4; phototx, phototherapy; PsA, psoriatic arthritis; SpA, spondyloarthritis; SSZ, sulfasalazine; TNF, tumour necrosis factor; vit, vitamin.

*OTEZLA is not included in the GRAPPA recommendation for axial disease.

CS, corticosteroid; DMARDs, disease-modifying antirheumatic drugs; GRAPPA, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; IA, intraarticular; IL, interleukin; LEF, leflunomide; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; PDE4, phosphodiesterase 4; phototx, phototherapy; PsA, psoriatic arthritis; SpA, spondyloarthritis; SSZ, sulfasalazine; TNF, tumour necrosis factor; vit, vitamin.

Reference: 1. Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060-1071.


Select an e-mail client to share

close x